Loading…
Loading…
QRON (Qrons Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
QRON does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for QRON and 80,000+ other tickers.
See exactly how QRON's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for QRON and 80,000+ other tickers.
Qrons, Inc. is a biotechnology company, which engages in the development of treatments and technologies for neuronal and infectious diseases. Its proprietary patents include Techniques for Promoting Neuronal Recovery, Therapeutic Polypseudorotaxane Hydrogels, and Tellurium Compositions and Techniques for Use Therewith. The company was founded by Jonah Martin Meer and Ido Merfeld on August 22, 2016 and is headquartered in Glendale, CA.
Cognitive performance and functional wellness brand expands its focus across mental readiness, active lifestyles and everyday performance LOS ANGELES, Aug. 18, 2026 /PRNewswire/ -- First Person (OTCMarkets: QRON), a cognitive performance and functional wellness company and a wholly owned subsidiary of Qrons, Inc., today announced the next phase of its growth following early consumer momentum for Think Fast™, its premium functional coffee powered by proprietary Crystallized Lion's Mane technology. Think Fast™ has quickly become one of First Person's fastest-growing products, driven by consumers incorporating it into routines centered on focus, productivity, and mental performance.
NEW YORK, NY / ACCESSWIRE / November 20, 2023 / Qrons Inc. (OTCQB:QRON) announced that Professor Shiri Navon-Venezia has agreed to join Qrons Scientific Advisory Board. Professor Venezia is Professor of Microbiology, Head of Bacterial Pathogens & Antibiotic Resistance Lab in Ariel University.
NEW YORK, NY / ACCESSWIRE / August 23, 2023 / Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products treatments and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the launch of its updated website at www.qrons.com. This update will provide investors and the public an overview of the company's strides in dealing with infectious disease and sepsis with a focus on antibiotic resistant bacteria, which is becoming the most prominent and rapidly growing worldwide cause of illness and death.
NEW YORK, NY / ACCESSWIRE / August 14, 2023 / Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the filing on August 9, of a United States Provisional Patent Application entitled Tellurium Compositions and Techniques For Use Therewith. This filing is in furtherance of its Neuronal and Infectious Disease treatments development, including sepsis.
NEW YORK, NY / ACCESSWIRE / July 20, 2023 / Qrons Inc. (OTCQB:QRON) announced today the signing of a License Agreement Term Sheet effective July 17, 2023 with Professors Benjamin Sredni & Michael Albeck of Bar Ilan University in Israel for an exclusive world-wide, perpetual license of their IP in Tellurium based compounds. The IP will be used together Qrons' IP created by Dr. Ido Merfeld, Qrons co-founder as part of a new research program to experiment and commercialize the therapeutic effect of certain Tellurium based compounds on antibiotic resistance bacterial infections, Sepsis and Traumatic Brain Injuries.